The ERMBT estimates "in vivo" CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-"N"-methyl)-erythromycin.
The ERMBT estimates "in vivo" CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-"N"-methyl)-erythromycin.